Sign In
Buy EVGN
Evogene Earnings Calls
| Release date | Nov 20, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | 650K |
| Revenue actual | - |
| Expected change | +/- 6.07% |
| Release date | Aug 19, 2025 |
| EPS estimate | -₪2.13 |
| EPS actual | -₪0.618 |
| EPS Surprise | 71.02% |
| Revenue estimate | 905K |
| Revenue actual | 884K |
| Revenue Surprise | -2.32% |
| Release date | May 21, 2025 |
| EPS estimate | -₪1.88 |
| EPS actual | -₪1.42 |
| EPS Surprise | 24.35% |
| Revenue estimate | 1.943M |
| Revenue actual | 9.143M |
| Revenue Surprise | 370.71% |
| Release date | Mar 05, 2025 |
| EPS estimate | -₪0.760 |
| EPS actual | ₪0.0600 |
| EPS Surprise | 107.89% |
| Revenue estimate | 5M |
| Revenue actual | 5.857M |
| Revenue Surprise | 17.13% |
Last 4 Quarters for Evogene
Below you can see how EVGN.TA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 05, 2025 |
| Price on release | ₪495.40 |
| EPS estimate | -₪0.760 |
| EPS actual | ₪0.0600 |
| EPS surprise | 107.89% |
| Date | Price |
|---|---|
| Feb 28, 2025 | ₪502.70 |
| Mar 02, 2025 | ₪516.20 |
| Mar 03, 2025 | ₪521.50 |
| Mar 04, 2025 | ₪496.00 |
| Mar 05, 2025 | ₪495.40 |
| Mar 06, 2025 | ₪506.40 |
| Mar 07, 2025 | ₪506.40 |
| Mar 09, 2025 | ₪526.00 |
| Mar 10, 2025 | ₪520.20 |
| 4 days before | -1.45% |
| 4 days after | 5.01% |
| On release day | 2.22% |
| Change in period | 3.48% |
| Release date | May 21, 2025 |
| Price on release | ₪436.00 |
| EPS estimate | -₪1.88 |
| EPS actual | -₪1.42 |
| EPS surprise | 24.35% |
| Date | Price |
|---|---|
| May 16, 2025 | ₪430.40 |
| May 18, 2025 | ₪462.00 |
| May 19, 2025 | ₪459.00 |
| May 20, 2025 | ₪477.90 |
| May 21, 2025 | ₪436.00 |
| May 22, 2025 | ₪417.30 |
| May 23, 2025 | ₪417.30 |
| May 25, 2025 | ₪419.70 |
| May 26, 2025 | ₪429.30 |
| 4 days before | 1.30% |
| 4 days after | -1.54% |
| On release day | -4.29% |
| Change in period | -0.256% |
| Release date | Aug 19, 2025 |
| Price on release | ₪454.50 |
| EPS estimate | -₪2.13 |
| EPS actual | -₪0.618 |
| EPS surprise | 71.02% |
| Date | Price |
|---|---|
| Aug 14, 2025 | ₪440.70 |
| Aug 15, 2025 | ₪440.70 |
| Aug 17, 2025 | ₪450.30 |
| Aug 18, 2025 | ₪460.80 |
| Aug 19, 2025 | ₪454.50 |
| Aug 20, 2025 | ₪420.30 |
| Aug 21, 2025 | ₪419.50 |
| Aug 22, 2025 | ₪419.50 |
| Aug 24, 2025 | ₪434.40 |
| 4 days before | 3.13% |
| 4 days after | -4.42% |
| On release day | -7.52% |
| Change in period | -1.43% |
| Release date | Nov 20, 2025 |
| Price on release | - |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Nov 12, 2025 | ₪407.60 |
| Nov 13, 2025 | ₪399.10 |
| Nov 14, 2025 | ₪399.10 |
| Nov 17, 2025 | ₪398.70 |
| Nov 18, 2025 | ₪391.00 |
Evogene Earnings Call Transcript Summary of Q2 2025
Evogene completed a strategic pivot in H1 2025 to center the company on its ChemPass AI small-molecule discovery platform and to monetize non-core assets. Key near-term financials: H1 2025 revenue was ~$3.2M (vs. $2.3M prior year), operating expenses fell to ~$7.7M (vs. ~$11.1M), net loss was ~$7.7M (vs. ~$9.8M), and consolidated cash as of June 30, 2025 was ~$11.7M (this figure excludes proceeds from the ICL transactions completed in Q3). Material monetization actions: sale of most of Lavie Bio to ICL for $15.25M and sale of the MicroBoost AI for Ag platform to ICL for $3.5M (transactions completed in July/Q3), plus an ATM raise of $4.4M in June. Management says these actions, along with cost reductions (headcount cuts ~30% at Evogene and >40% at AgPlenus) and subsidiary streamlining, leave the company with an operational runway of approximately 18 months. Technology and business development milestones: ChemPass AI v1 (a generative AI foundation model for small molecule design built with Google Cloud and trained on a proprietary dataset of ~38 billion molecular structures) is complete and intended to drive collaborations in both pharma and ag crop-protection; management is pursuing pharma collaborations (first announced with Prof. Ehud Gazit) and plans a dedicated BD arm to accelerate pharma partnerships. Subsidiary status and catalysts: Biomica has been streamlined, leadership changed, holds roughly $4M cash and aims to complete its clinical trial in early 2026 while seeking partners; Casterra is driving near-term sales from castor seed/grain with “hundreds of tons” of seed inventory and expanding trials in Brazil and Kenya; Lavie Bio is largely divested and expected to distribute funds to shareholders. Guidance/catalysts investors should watch: additional collaboration announcements (pharma and ag), further productization of ChemPass AI, disclosure of field-trial results from Casterra, Biomica clinical-trial progress (early 2026), and H2 2025 financials reflecting the full benefit of cost reductions and ICL sale proceeds.
